Status:
RECRUITING
Better Leukemia Diagnostics Through AI (BELUGA)
Lead Sponsor:
Munich Leukemia Laboratory
Conditions:
Hematologic Malignancy
Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
To the best of our knowledge, BELUGA will be the first prospective trial investigating the usefulness of deep learning-based hematologic diagnostic algorithms. Taking advantage of an unprecedented col...
Detailed Description
In numerous recent studies, deep neuronal networks (DNN) have been leveraged to examine the usefulness of artificial intelligence (AI)-based DNN for diagnostic purposes. In essence, they have successf...
Eligibility Criteria
Inclusion
- Patients having been diagnosed with a suspected hematological disorder
- The suspected diagnoses constitute a primary diagnosis
- Only samples of patients min.18 years of age will be used
- Samples must suffice quality attributes which are denoted in "Exclusion Criteria"
Exclusion
- The sample is not fit for state-of-the-art diagnosis or fails initial quality control. For quality insurance, we will exclude samples in heparin- instead of EDTA. Samples with damage due to atmospheric reasons (freeze-thaw damage or elevated temperature) will be excluded.
- Samples with too scarce material jeopardizing routine gold-standard diagnosis will be excluded.
- Bone marrow aspirates without sufficient material to assess malignant or healthy hematopoiesis.
Key Trial Info
Start Date :
January 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2025
Estimated Enrollment :
25000 Patients enrolled
Trial Details
Trial ID
NCT04466059
Start Date
January 5 2020
End Date
July 31 2025
Last Update
December 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MLL Munich Leukemia Laboratory
Munich, Bavaria, Germany, 81377